Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 51,299

Document Document Title
WO/2016/105535A3
Provided herein is a pathway for adipocyte energy consumption regulation involving ARID5B, genetic variant rsl421085, IRX3, and IRX5. Compositions and methods for modulating the pathway in vitro and in vivo for anti-cachectic and anti-ob...  
WO/2016/104617A1
This compound represented by general formula (I) and having a quinoline skeleton has a strong Axl inhibitory activity. Consequently, this compound can be a therapeutic agent for Axl-related diseases, for example, cancers such as acute my...  
WO/2016/104451A1
The present invention relates to a compound represented by the following general formula (1) [wherein X represents an oxygen atom, an imino group, a sulfur atom, sulfinyl, or sulfonyl, R1, R2, and R3 each independently represent a hydrog...  
WO/2016/104678A1
Provided is a novel medical composition capable of promoting fibrinolysis. The medical composition for promoting fibrinolysis contains edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of those. In addition to edoxaban...  
WO/2016/095642A9
Provided in the application is a interleukin 15 (IL-15) protein complex. The IL-15 protein complex consists of a soluble fusion proteins (I) and (II), wherein the fusion protein (I) is a IL-15 polypeptide or a functionality fragment ther...  
WO/2016/095778A1
A method for treatment and prevention of air pollution-related diseases, especially diseases related to atmospheric PM2.5 in subjects. The method comprises administering an effective amount of a polyunsaturated fatty acid and vitamin E t...  
WO/2016/095642A1
Provided in the application is a interleukin 15 (IL-15) protein complex. The IL-15 protein complex consists of a soluble fusion proteins (I) and (II), wherein the fusion protein (I) is a IL-15 polypeptide or a functionality fragment ther...  
WO/2016/094406A1
Disclosed are anti-miR compositions and methods of use of the same for treatment of or reducing the occurrence of thrombosis and thrombosis related diseases and disorders by reducing platelet activation.  
WO/2016/093285A1
A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics i...  
WO/2016/094659A1
A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s-NH-(CH2)t, (CH2)s-0-(CH2)t, or (CH2)S-C(NH2)- (CH2)v-NH-(CH2)t,where s, t and v are each, independ...  
WO/2016/090800A1
Disclosed is an anti-platelet aggregation drug, comprising an atractylenolide compound or a derivative thereof. The atractylenolide compound has a structural formula represented by formula (I), wherein R1 represents H or C1-C10 linear al...  
WO/2016/092329A1
This invention relates to a new use of compounds that are angiotensin II receptor agonists, specifically agonists of the angiotensin II type 2 receptor (the AT2 receptor), and especially agonists that bind selectively to the AT2 receptor...  
WO/2016/090188A1
In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the comp...  
WO/2016/086768A1
Disclosed is chimeric nuclease TALE-ISceI, in which FokI in TALEN is replaced with fusion protein obtained by transformed I-SceI. The chimeric nuclease TALE-ISceI can specifically recognize and repair a β thalassemia β-globin gene and ...  
WO/2016/087343A1
The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to a method for producing same, to the use thereof alone or in combinations for treating and/or preventing diseases, and to the use thereof for prod...  
WO/2016/084816A1
Provided is a bicyclic compound having an inhibitory effect on acetyl-CoA carboxylase. A compound represented by the formula: (in the formula, each of the symbols is as defined in the specification) or a salt thereof has an inhibitory ef...  
WO/2016/078145A1
A qi-replenishing and blood-benefiting tincture comprising the following components in parts by weight: 20-30 parts of Codonopsis pilosula, 20-30 parts of Wolfiporia extensa, 20-30 parts of radix Rehmanniae, 10-16 parts of Atractylodes m...  
WO/2016/077878A1
A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.  
WO/2016/074640A1
A pharmaceutical composition comprising dabigatran etexilate, and preparation method and use thereof, and solid preparation comprising the pharmaceutical composition; the pharmaceutical composition comprises a vitamin C layer and a dabig...  
WO/2016/076780A1
A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glu...  
WO/2016/074033A1
Methods and compositions comprising Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) are provided for treating impaired blood flow. The compositions and methods can be used to treat, for example, ischemia and wounds.  
WO/2016/076744A1
The invention represents a pharmaceutical composition in the form of a sterile powder for topical use with a homeostatic and wound-healing effect, the composition comprising a carboxylated derivative of a glucopyranose-based polymer as t...  
WO/2016/071511A1
The present invention relates to a method for treating mast cell activation syndrome (MCAS) in human patients comprising administering a tyrosine kinase inhibitor to patients in need of, wherein said tyrosine kinase inhibitor is an inhib...  
WO/2016/070696A1
Disclosed is an oral dosing preparation of dabigatran etexilate or a pharmacologically acceptable salt thereof and a preparation method thereof.  
WO/2016/073424A1
The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range ...  
WO/2016/073668A1
In some embodiments, the invention provides methods for detecting an aberrant fibrinolysis condition in a patient. The method includes subjecting a blood sample from the patient to a viscoelastic analysis in the presence of a known amoun...  
WO/2016/073837A1
Factor IX proteins are described with an increase in the number of glycosylation sites and other modifications to provide Factor IX proteins that have higher specific activity and a longer useful clotting function relative to wild type o...  
WO/2016/073416A1
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with G-CSF or in combination with EPO, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods ...  
WO/2016/072519A1
Provided is a cell population containing differentiated cells that can be obtained by inducing the differentiation of pluripotent stem cells, wherein the content ratio of undifferentiated pluripotent stem cells is 0.2% or less.  
WO/2016/071216A1
The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in pa...  
WO/2016/070257A1
The invention describes water-soluble iron (III) oxide-hydroxide complexes prepared from various sources of iron, amino acids and carboxylic acids, and pharmaceutical or food compositions containing same. The iron (III) complexes do not ...  
WO/2016/066128A1
A pharmaceutical composition containing ginkgolide B and an Xa factor inhibitor xaban, a preparation method and use of the pharmaceutical composition, wherein the xaban is selected from Rivaroxaban, Apixaban, Edoxaban, Razaxaban and Otam...  
WO/2016/065602A1
Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are provided as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of me...  
WO/2016/069925A1
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.  
WO/2016/066172A1
The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of...  
WO/2016/066134A1
The present invention relates to six-membered ring benzo derivatives as a DPP-4 inhibitor and a use thereof. In particular, the present invention relates to a compound as shown by formula I, a pharmaceutical composition containing the co...  
WO/2016/070050A1
Antibodies and antigen-binding antibody fragments that bind to GPIIb/IIIa and chimeric polypeptides comprising these binding molecules are disclosed. Some of these antibodies and antigen-binding antibody fragments preferentially bind GPI...  
WO/2016/066555A1
There is provided polymorphs of ferric maltol. Such forms may be useful in the treatment of iron deficiency with or without anaemia, such as iron deficiency anaemia.  
WO/2016/066100A1
A pharmaceutical composition containing ginkgolide B and an ADP receptor antagonist, a preparation method thereof and use thereof in preparation of antiplatelet drugs, wherein the ADP receptor antagonist is clopidogrel, prasugrel, ticagr...  
WO/2016/065582A1
The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the thera...  
WO/2016/063990A1
The present invention relates to a compound represented by general formula (1). (The definition of each group in the formula is as described in the specification.) The compound is useful as a prophylactic and/or therapeutic agent for KCN...  
WO/2016/063228A1
The present invention relates to a dosage regimen of ST10 (ferric maltol) for use in the treatment of patients suffering from iron deficiency with or without anaemia. The invention specifically relates to use of ST10 wherein the dose is ...  
WO/2016/062245A1
Disclosed herein are methods and formulation for enhancing oral availability of CPT-11 during cancer therapy while at the same time, reducing its gastrointestinal (GI) toxicity, thus the methods and formulations as disclosed herein may a...  
WO/2016/063811A1
Disclosed is a dialysis agent-filled body which can be used in the preparation of an artificial perfusion solution for hemodialysis use. The dialysis agent-filled body according to the present invention comprises: an agent A-filled body ...  
WO/2016/063933A1
Provided is a heterocyclic compound that has an excellent RBP4 reducing effect and is useful as a preventive or therapeutic drug for diseases or symptoms mediated by a rise in RBP4 or by retinol supplied by RBP4. A compound represented b...  
WO/2016/061611A1
The present invention relates to improved clotting compositions for producing high quality blood serum samples for analyte testing, such as for pathology testing and other biological assays. In particular, the present invention relates t...  
WO/2016/063480A1
A peritoneal dialysis fluid production apparatus 1 is equipped with: a vessel 4 which has hydrogen permeability and has a preset volume; a dialysis fluid 6 which is accommodated in the vessel 4; a hydrogen water storage tank 2 in which t...  
WO/2016/059162A1
Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of different diseases. More particularly, the application provides for the administration of CSF to the intrathe...  
WO/2016/059588A1
The present invention relates to a non-aqueous, stable and ready-to-use injectable composition of bivalirudin or pharmaceutically acceptable salt(s) or co-crystals thereof; and processes for its preparation, it is not required to reconst...  
WO/2016/058144A1
Cyclic sulfonamide derivatives of Formula (I) or a pharmaceutically acceptable salt thereof are disclosed.  

Matches 601 - 650 out of 51,299